Download PDF
Thromb Haemost 2008; 99(04): 794-795
DOI: 10.1160/TH07-10-0628
Letters to the Editor
Schattauer GmbH

RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy

Peter E. Westerweel
1   Department of Vascular Medicine, University Medical Center Utrecht, The Netherlands
,
Ton J. Rabelink
2   Department of Nephrology and Hypertension, Leiden University Medical Center, The Netherlands
,
Maarten B. Rookmaaker
1   Department of Vascular Medicine, University Medical Center Utrecht, The Netherlands
,
Hermann-Josef Gröne
3   Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany C
,
Marianne C. Verhaar
1   Department of Vascular Medicine, University Medical Center Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 21 October 2007

Accepted after major revision: 12 February 2008

Publication Date:
25 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-713.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Veillard NR, Kwak B, Pelli G. et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-261.
    CrossrefPubMedGoogle Scholar
  • 3 Schober A, Manka D, von Hundelshausen P. et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529.
    CrossrefPubMedGoogle Scholar
  • 4 Wu H, Ghosh S, Perrard XD. et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007; 115: 1029-1038.
    CrossrefPubMedGoogle Scholar
  • 5 Matter CM, Handschin C. RANTES (regulated on activation, normal T cell expressed and secreted), inflammation, obesity, and the metabolic syndrome. Circulation 2007; 115: 946-948.
    CrossrefPubMedGoogle Scholar
  • 6 Epstein SE, Stabile E, Kinnaird T. et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004; 109: 2826-2831.
    CrossrefPubMedGoogle Scholar
  • 7 Weber C. Chemokines take centre stage in vascular biology. Thromb Haemost 2007; 97: 685-687.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730-737.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Ambati BK, Anand A, Joussen AM. et al. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci 2003; 44: 590-593.
    CrossrefPubMedGoogle Scholar
  • 10 Rookmaaker MB, Verhaar MC, De Boer HC. et al. Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo. Am J Physiol Renal Physiol 2007; 293: F624-F630.
    CrossrefPubMedGoogle Scholar
  • 11 Jain RK, Finn AV, Kolodgie FD. et al. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007; 4: 491-502.
    CrossrefPubMedGoogle Scholar